QGEN Qiagen NV

HILDEN and ROSTOCK, Germany and GERMANTOWN, Maryland, October 9, 2017 /PRNewswire/ --

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG today announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company providing insights into the complex interaction between genetics, biochemistry and clinical phenotypes of patients with hereditary disorders. More than 4,000 known genetic disorders are estimated to affect roughly 1 in 10 individuals.

Click here for the full press release
https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-09-Centogene?sc_lang=en

Contacts:
QIAGEN
Public Relations
Dr. Thomas Theuringer
e-mail: pr@QIAGEN.com
+49-2103-29-11826

Investor Relations
John Gilardi
e-mail: ir@QIAGEN.com
+49-2103-29-11711

CENTOGENE
CEO´s office
Doreen Niemann
e-mail: press@centogene.com
+49-381-203-652-181

SOURCE Qiagen N.V.